Group Health negative AMPYRA review updated on October 4, 6:53pm
Looks like another Questcor in the making.
Group Health updates coverage and withdraws Ampyra for MS, which was revised on Thursday, October 4 at 6:53pm and published today on their website - so this is a new update! Search Ampyra and you can download the pdf. Then go to Properties of the downloaded file to verify the revision date (October 4) for this data.:
Drug Name: Dalfampridine (Ampyra) Dosage, Route: Tablet, oral
Drug Class/Indication: Multiple sclerosis
Decision: Add criteria.
GH Closed Formulary GH Open Formulary Medicare Part D
Formulary Status Non-formulary with
Tier 3 with criteria Tier 4 (non-preferred)
Medical necessity review required.
Dalfampridine provides outcomes of questionable clinical significance and lacks long-term safety data
Analysts rushing to defend the stock?? This is exactly what happened to QCOR before the 50%+ plunge last month on the United Health Acthar negative update posted on UNH's website, wehn it took two days for the market to react with a massive sell-off. ACOR=QCOR, wow almost the same ticker symbols too. Bad omen - be careful.